The rapid growth in the biotechnology equity market and the explosion in the number of biotechnology initial public offerings (IPOs)have created unprecedented wealth in the western hemisphere in the form of restricted securities shares(equity)in newly founded companies that can be traded only in compliance with regulations imposed by the relevant authorities.